Adaptimmune Therapeutics plc (NASDAQ:ADAP) is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.25 per share.
For the full year, analysts predict revenues of $ 3.97 million, while looking forward to loss of $ 0.91 per share.
Previous Quarter Performance
Adaptimmune Therapeutics plc outlined loss for the second quarter of $ 0.04 per share, from the revenue of $ 0.50 million. The quarterly revenues escalated 212.50 percent compared with the same quarter last year. Street analysts expected Adaptimmune Therapeutics plc to report loss of $ 0.23 per share on revenue of $ 0.93 million for the second quarter. The bottom line results beat street analysts by $ 0.19 or 82.61 percent, at the same time, top line results fell short of analysts by $ 0.43 million or 46.24 percent.
Stock Performance
Shares of Adaptimmune Therapeutics plc traded up $ 0.07 or 1.34 percent on Wednesday, reaching $ 5.30 with volume of 2.05 million shares. Adaptimmune Therapeutics plc has traded high as $ 5.75 and has cracked $ 5.21 on the downward trend
The closing price of $ 5.30, representing a 636.62 % increase from the 52 week low of $ 0.71 and a 60.97 % decrease over the 52 week high of $ 13.40.
The company has a market capital of $ 819.44 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Adaptimmune Therapeutics plc will be hosting a conference call at 8:00 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.adaptimmune.com
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The companys specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
